7-OH-DPAT-Induced Inhibition of Norepinephrine Release in PC12 Cells

Pharmacology

Volumn 70, Issue 3, 2004, Pages 130-139

  Chu, Eugenia ^a   Chu, Jane ^b   Socci, Robin R ^c   Chu, Teh Ching ^c  

^a UNIVERSITY OF GEORGIA   (United States)

^b SPELMAN COLLEGE   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

7 OH DPAT; cAMP cGMP; D2 D3 receptors; Immunoblotting; Immunocytochemistry; Intracellular Ca2+; mRNA; Norepinephrine release; PC12 cells

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 4 AMINOPYRIDINE; CALCIUM ION; CARBACHOL; CYCLIC GMP; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; MESSENGER RNA; NERVE GROWTH FACTOR; NORADRENALIN; POTASSIUM ION; RACLOPRIDE;

ANIMAL CELL; ARTICLE; CELL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; NONHUMAN; NORADRENALIN RELEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CALCIUM; CARBACHOL; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOCHEMISTRY; NERVE GROWTH FACTOR; NOREPINEPHRINE; PC12 CELLS; POTASSIUM CHLORIDE; RACLOPRIDE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAHYDRONAPHTHALENES;

EID: 0442324655     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074976     Document Type: Article

References (46)

1. Schwartz JC, Diaz J, Pilon C, Sokoloff P: Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 2000;31:277-287.
2. 3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci USA 2001;98:625-628.
3. Kebabian JW, Calne DB: Multiple receptors for dopamine. Nature 1979;277:93-96.
4. Civelli O, Bunzow JR, Grandy DK: Molecular diversity of dopamine receptors. Annu Rev Pharmacol Toxicol 1993;33:281-307.
5. Gingrich JA, Caron MG: Recent advances in the molecular biology of dopamine receptors. Ann Rev Neurosci 1993;16:299-321.
6. 3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 1997;49:231-252.
7. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol Rev 1998;78:189-225.
8. 2 receptor. Trends Pharmacol Sci 1989;10:74-77.
9. 2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology 2003;28:1317-1327.
10. 3 dopamine receptors in differentiated neuroblastoma x glioma NG108-15 cells. Br J Pharmacol 1994;111:391-393.
11. 3 receptor. J Pharmacol Exp Ther 1997;52:508-514.
12. 3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol 1999;56:1025-1030.
13. 3 dopamine autoreceptors do not activate G-protein-gated inwardly rectifying potassium channel currents in substantia nigra dopamine neurons. J Neurosci 2003;23:5693-5697.
14. Kozminski KD, Gutman DA, Davila V, Sulzer D, Ewing AG: Voltammetric and pharmacological characterization of dopamine release from single exocytotic events at rat pheochromocytoma (PC12) cells. Anal Chem 1998;70:3123-3130.
15. 2+-induced vesicular catecholamine release from rat PC12 cells. Brain Res 2002;957:25-36.
16. 3H]- dopamine release in undifferentiated and differentiated PC12 cells. Neurochem Int 1990;17:197-203.
17. 2+/calmodulin kinase II inhibitor KN-62. J Cell Sci 1995;108:2619-2628.
18. Dupont JL, Janoshazi A, Bellahcene M, Mykita S, de Barry J: Reversible protein kinase C activation in PC12 cells: effect of NGF treatment. Eur J Neurosci. 2000;12:215-226.
19. Chu TC, Socci RR, Ogidigben MJ, Potter DE: Potential mechanisms of moxonidine-induced ocular hypotension: Role of norepinephrine. J Ocul Pharmacol Ther 1997;13:489-496.
20. 3 receptor agonist. J Pharmacol Exp Ther 2000;293:710-716.
21. Chu E, Chu TC, Potter DE: Potential sites of action of TNPA: A dopamine-2 receptor agonist. Exp Eye Res 1999;69:611-616.
22. Ammer H, Schulz R.: Regulation of stimulatory adenylyl cyclase signaling during forskolininduced differentiation of mouse neuroblastoma x rat glioma (NG108-15) cells. Neurosci Lett 1997;230:143-146.
23. 2+ in individual small cells using fluorescence microscopy with dual excitation wavelengths. Cell Calcium 1985;6:145-157.
24. 2+/calmodulin- dependent protein kinase II in PC12 cells alters cell growth, morphology, and nerve growth factor-induced differentiation. J Neurosci 1997;17:924-931.
25. 2-like dopamine autoreceptor activation reduces quantal size in PC12 cells. J Neurosci 1998;18:5575-5585.
26. 4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. J Clin Endocrinol Metab 2001;86:4460-4467.
27. Ikemoto A, Kobayashi T, Watanabe S, Okuyama H: Membrane fatty acid modifications of PC12 cells by arachidonate or docosahexaenoate affect neurite outgrowth but not norepinephrine release. Neurochem Res 1997;22:671-678.
28. Hattori T, Maehashi H, Miyazawa T, Naito M: Enhancement of dopamine release by propylene glycol in PC12 cells. Res Commun Mol Pathol Pharmacol 2000;107:323-329.
29. Courtney ND, Howlett AC, Westfall TC: Dopaminergic regulation of dopamine release from PC12 cells via a pertussis toxin-sensitive G protein. Neurosci Lett 1991;122:261-264.
30. 3H]-acetylcholine release in rat striatal synaptosomes. Brain Res 2000;874:116-122.
31. Mignini F, Bronzetti E, Felici L, Ricci A, Sabbatini M, Tayebati SK, Amenta F: Dopamine receptor immunohistochemistry in the rat choroid plexus. J Auton Pharmacol 2000;20:325-332.
32. 3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci USA 2001;98:5258-5263.
33. Kline DD, Takacs KN, Ficker E, Kunze DL: Dopamine modulates synaptic transmission in the nucleus of the solitary tract. J Neurophysiol 2002;88:2736-2744.
34. Surmeier DJ, Song WJ, Yan Z: Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 1996;16:6579-6591.
35. 3 dopamine receptor in cellular and organismal function. Psychopharmacology (Berl) 1998;135:1-16.
36. 2 receptor in PC-12 cells and regulation of membrane conductances by dopamine. Am J Physiol 1997;273:C1143-C1150.
37. 3 receptor protein in the rat kidney. Hypertension 1998;32:886-895.
38. 3 dopamine receptor: Pharmacologic properties and development of antibodies. J Pharmacol Exp Ther 1993;264:1002-1011.
39. 2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase: A study with sitedirected mutant Gi alpha proteins. J Biol Chem 1994;269:23120-23127.
40. Jackson DM, Westlind-Danielsson A: Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 1994;64:291-370.
41. Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: Distinct Galpha and Gbetagamma requirements. Mol Endocrinol 2002;16:2393-2404.
42. 2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 2002;301:1166-1178.
43. 2+ stores in a sympathetic neuron cell line. Cell Calcium 1996;19:399-407.
44. 2+ release and entry during contraction elicited by norepinephrine in rat resistance arteries. Am J Physiol 1999;276:H300-H308.
45. 2+ increases in rat lactotroph cells: Evidence of a dual mechanism of action. J Biol Chem 1987;262:13920-13927.
46. + channels in pheochromocytoma cells. J Gen Physiol 1988;91:73-106.